Pharsight

Drugs that contain Ponesimod

1. Ponvory patents expiration

PONVORY's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE43728 JANSSEN PHARMS Thiazolidin-4-one derivatives
Nov, 2024

(5 months from now)

US9062014 JANSSEN PHARMS Crystalline forms of (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-0-tolyl-thiazolidin-4-one
May, 2032

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9000018 JANSSEN PHARMS Thiazolidin-4-one-derivatives
Nov, 2024

(5 months from now)

US8273779 JANSSEN PHARMS Thiazolidin 4-one derivatives
Dec, 2025

(1 year, 6 months from now)

US10220023 JANSSEN PHARMS Dosing regimen for a selective S1P1 receptor agonist
Dec, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 18, 2026

NCE-1 date: 18 March, 2025

Market Authorisation Date: 18 March, 2021

Treatment: Reduction of circulating lymphocytes in treating relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive dise...

Dosage: TABLET;ORAL

More Information on Dosage

PONVORY family patents

Family Patents